RecruitingNot ApplicableNCT05885022

Feasibility Clinical Evaluation of the Calibreye System


Sponsor

Myra Vision Inc.

Enrollment

60 participants

Start Date

May 31, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate the safety and feasibility of the Calibreye System in patients with open angle glaucoma.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new device called the Calibreye System for treating glaucoma — a condition where fluid builds up in the eye and damages the optic nerve. The device is designed to drain excess fluid and lower eye pressure. **You may be eligible if...** - You have open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma - Your eye pressure is between 18 and 45 mmHg before the procedure - Your vision has been measurably affected by glaucoma - The tissue around your eye in the target area is healthy and mobile **You may NOT be eligible if...** - You have angle-closure glaucoma or certain other types of secondary glaucoma - You have had most types of prior eye surgery (other than uncomplicated cataract surgery more than 3 months ago) - You have had a previous glaucoma drainage device in the target area - You have an active eye infection or inflammation - You have had corneal surgery or have corneal scarring Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECalibreye System

Implantation of a glaucoma device to reduce intraocular pressure


Locations(4)

Dr. Agarwal's Eye Hospital Ltd.

Chennai, India

Centro Oftalmologico de Chihuahua

Chihuahua City, Mexico

Oftalmología Láser de Puebla S.C.

Puebla City, Mexico

Panama Eye Center

Panama City, Panama

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05885022


Related Trials